792 related articles for article (PubMed ID: 17692804)
1. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
Annunziata CM; Davis RE; Demchenko Y; Bellamy W; Gabrea A; Zhan F; Lenz G; Hanamura I; Wright G; Xiao W; Dave S; Hurt EM; Tan B; Zhao H; Stephens O; Santra M; Williams DR; Dang L; Barlogie B; Shaughnessy JD; Kuehl WM; Staudt LM
Cancer Cell; 2007 Aug; 12(2):115-30. PubMed ID: 17692804
[TBL] [Abstract][Full Text] [Related]
2. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Keats JJ; Fonseca R; Chesi M; Schop R; Baker A; Chng WJ; Van Wier S; Tiedemann R; Shi CX; Sebag M; Braggio E; Henry T; Zhu YX; Fogle H; Price-Troska T; Ahmann G; Mancini C; Brents LA; Kumar S; Greipp P; Dispenzieri A; Bryant B; Mulligan G; Bruhn L; Barrett M; Valdez R; Trent J; Stewart AK; Carpten J; Bergsagel PL
Cancer Cell; 2007 Aug; 12(2):131-44. PubMed ID: 17692805
[TBL] [Abstract][Full Text] [Related]
3. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.
Demchenko YN; Glebov OK; Zingone A; Keats JJ; Bergsagel PL; Kuehl WM
Blood; 2010 Apr; 115(17):3541-52. PubMed ID: 20053756
[TBL] [Abstract][Full Text] [Related]
4. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.
Pham LV; Fu L; Tamayo AT; Bueso-Ramos C; Drakos E; Vega F; Medeiros LJ; Ford RJ
Blood; 2011 Jan; 117(1):200-10. PubMed ID: 20889926
[TBL] [Abstract][Full Text] [Related]
5. Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation.
Razani B; Zarnegar B; Ytterberg AJ; Shiba T; Dempsey PW; Ware CF; Loo JA; Cheng G
Sci Signal; 2010 May; 3(123):ra41. PubMed ID: 20501937
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.
Rahal R; Frick M; Romero R; Korn JM; Kridel R; Chan FC; Meissner B; Bhang HE; Ruddy D; Kauffmann A; Farsidjani A; Derti A; Rakiec D; Naylor T; Pfister E; Kovats S; Kim S; Dietze K; Dörken B; Steidl C; Tzankov A; Hummel M; Monahan J; Morrissey MP; Fritsch C; Sellers WR; Cooke VG; Gascoyne RD; Lenz G; Stegmeier F
Nat Med; 2014 Jan; 20(1):87-92. PubMed ID: 24362935
[TBL] [Abstract][Full Text] [Related]
7. Maximal adamantyl-substituted retinoid-related molecule-induced apoptosis requires NF-κB noncanonical and canonical pathway activation.
Farhana L; Dawson MI; Murshed F; Fontana JA
Cell Death Differ; 2011 Jan; 18(1):164-73. PubMed ID: 20671747
[TBL] [Abstract][Full Text] [Related]
8. An atypical E3 ligase zinc finger protein 91 stabilizes and activates NF-kappaB-inducing kinase via Lys63-linked ubiquitination.
Jin X; Jin HR; Jung HS; Lee SJ; Lee JH; Lee JJ
J Biol Chem; 2010 Oct; 285(40):30539-47. PubMed ID: 20682767
[TBL] [Abstract][Full Text] [Related]
9. XEDAR activates the non-canonical NF-κB pathway.
Verhelst K; Gardam S; Borghi A; Kreike M; Carpentier I; Beyaert R
Biochem Biophys Res Commun; 2015 Sep; 465(2):275-80. PubMed ID: 26260321
[TBL] [Abstract][Full Text] [Related]
10. A fourth IkappaB protein within the NF-kappaB signaling module.
Basak S; Kim H; Kearns JD; Tergaonkar V; O'Dea E; Werner SL; Benedict CA; Ware CF; Ghosh G; Verma IM; Hoffmann A
Cell; 2007 Jan; 128(2):369-81. PubMed ID: 17254973
[TBL] [Abstract][Full Text] [Related]
11. Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway.
He JQ; Saha SK; Kang JR; Zarnegar B; Cheng G
J Biol Chem; 2007 Feb; 282(6):3688-94. PubMed ID: 17158868
[TBL] [Abstract][Full Text] [Related]
12. Control of canonical NF-kappaB activation through the NIK-IKK complex pathway.
Zarnegar B; Yamazaki S; He JQ; Cheng G
Proc Natl Acad Sci U S A; 2008 Mar; 105(9):3503-8. PubMed ID: 18292232
[TBL] [Abstract][Full Text] [Related]
13. A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses.
de Oliveira KA; Kaergel E; Heinig M; Fontaine JF; Patone G; Muro EM; Mathas S; Hummel M; Andrade-Navarro MA; Hübner N; Scheidereit C
Genome Med; 2016 Mar; 8(1):28. PubMed ID: 26988706
[TBL] [Abstract][Full Text] [Related]
14. Noncanonical NF-κB signaling is limited by classical NF-κB activity.
Gray CM; Remouchamps C; McCorkell KA; Solt LA; Dejardin E; Orange JS; May MJ
Sci Signal; 2014 Feb; 7(311):ra13. PubMed ID: 24497610
[TBL] [Abstract][Full Text] [Related]
15. Methods to assess the activation of the alternative (noncanonical) NF-κB pathway by non-death TNF receptors.
Remouchamps C; Dejardin E
Methods Mol Biol; 2015; 1280():103-19. PubMed ID: 25736746
[TBL] [Abstract][Full Text] [Related]
16. TNF-α Modulation of Intestinal Tight Junction Permeability Is Mediated by NIK/IKK-α Axis Activation of the Canonical NF-κB Pathway.
Al-Sadi R; Guo S; Ye D; Rawat M; Ma TY
Am J Pathol; 2016 May; 186(5):1151-65. PubMed ID: 26948423
[TBL] [Abstract][Full Text] [Related]
17. Baculoviral inhibitors of apoptosis repeat containing (BIRC) proteins fine-tune TNF-induced nuclear factor κB and c-Jun N-terminal kinase signalling in mouse pancreatic beta cells.
Tan BM; Zammit NW; Yam AO; Slattery R; Walters SN; Malle E; Grey ST
Diabetologia; 2013 Mar; 56(3):520-32. PubMed ID: 23250032
[TBL] [Abstract][Full Text] [Related]
18. LATS2 inhibits the activity of NF-κ B signaling by disrupting the interaction between TAK1 and IKKβ.
Yao F; Zhou W; Zhong C; Fang W
Tumour Biol; 2015 Sep; 36(10):7873-9. PubMed ID: 25946971
[TBL] [Abstract][Full Text] [Related]
19. CDK12-mediated transcriptional regulation of noncanonical NF-κB components is essential for signaling.
Henry KL; Kellner D; Bajrami B; Anderson JE; Beyna M; Bhisetti G; Cameron T; Capacci AG; Bertolotti-Ciarlet A; Feng J; Gao B; Hopkins B; Jenkins T; Li K; May-Dracka T; Murugan P; Wei R; Zeng W; Allaire N; Buckler A; Loh C; Juhasz P; Lucas B; Ennis KA; Vollman E; Cahir-McFarland E; Hett EC; Ols ML
Sci Signal; 2018 Jul; 11(541):. PubMed ID: 30065029
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-κB-activating potential.
Yamato A; Soda M; Ueno T; Kojima S; Sonehara K; Kawazu M; Sai E; Yamashita Y; Nagase T; Mano H
Cancer Sci; 2015 Sep; 106(9):1137-42. PubMed ID: 26094954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
